MedTrace Logo

A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation

NCT05148299 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-11-28

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.

Conditions

  • Transplant-Associated Thrombotic Microangiopathy

Interventions

DRUG

Pegcetacoplan

20-cc glass vials-1080 mg

Sponsors & Collaborators

  • Apellis Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Study physician · Swedish Orphan Biovitrum AB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-12-08
Completion
2024-12-08
FDA Drug
Yes

Countries

  • United States
  • France
  • Greece
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05148299 on ClinicalTrials.gov